1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Revolution Medicines, Inc. Warrant

Revolution Medicines, Inc. Warrant

RVMDW
Revolution Medicines, Inc. WarrantUS flagNASDAQ Global Select
8.86
USD
+0.25
- -
37.78BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
20
50
43
29
35
12
- -
- -
- -
Operating Margin (%)
- -
-200
-108.15
-257.54
-639.7
-730.01
-4,207.12
- -
- -
- -
Depreciation Expense
1
2
3
7
7
10
9
12
17
17
Net Income, GAAP
-31
-42
-48
-108
-187
-249
-436
-600
-1,131
-1,372
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-207.24
-95.25
-251.63
-636.58
-702.95
-3,768.28
- -
- -
- -
Working Capital
2
55
91
407
529
598
1,735
2,164
1,785
1,678
LT Debt
- -
- -
- -
29
60
57
81
123
142
140
Total Equity
5
97
153
475
603
685
1,826
2,265
1,631
1,500
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
16
16
17
LT Borrowings
- -
- -
- -
LT Finance Leases
142
142
140
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
190
197
200
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,977
2,075
1,968
Cash, Cash Equivalents & STI
1,932
2,026
1,908
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
246
290
290
Payables & Accruals
189
208
246
ST Debt
16
16
17
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
40.65%
-27.98%
Free Cash Flow
- -
54.8%
60.94%
Net Income, GAAP
- -
61.48%
88.52%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Mark A. Goldsmith
Full Time Employees
883
Sector
Healthcare
Industry
Biotechnology
Address
700 Saginaw Drive Redwood City CA United States of America 94063
IPO Date
Feb 13, 2020
CIK
0001628171
Website
revmed.com
Similar Companies
Mabion S.A. (MAB.WA)
Strategic Partners A/S (STRAP.CO)
Prometheus Biosciences, Inc. (RXDX)
Prescient Therapeutics Limited (PSTTF)
Rezolute, Inc. (RZLT)
Nykode Therapeutics AS (NYKD.OL)
Business
Revolution Medicines, Inc. is a late-stage clinical oncology company developing innovative targeted therapies for cancers driven by RAS mutations. The company's research and development efforts are concentrated on a portfolio of RAS(ON) inhibitors, designed to directly inhibit various activated RAS protein variants, either as standalone treatments or in combination with other agents. Key assets in its pipeline include daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor progressing through pivotal Phase 3 clinical trials for metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer, having also received FDA Breakthrough Therapy Designation for pancreatic cancer with KRAS G12 mutations and Orphan Drug Designation. Additionally, elironrasib (RMC-6291), a selective RAS(ON) G12C inhibitor, is in clinical development, with FDA Breakthrough Therapy Designation for KRAS G12C-mutated non-small cell lung cancer. Another important candidate is zoldonrasib (RMC-9805), a selective RAS(ON) G12D inhibitor, also undergoing clinical investigation with plans for a Phase 3 trial in pancreatic cancer. Further pipeline compounds include mutant-selective RAS(ON) inhibitors such as RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company also pursues RAS companion inhibitors like RMC-4630 and RMC-5552 for comprehensive treatment strategies. Revolution Medicines has entered into strategic collaborations, including a significant $2 billion funding agreement with Royalty Pharma to advance its RAS(ON) inhibitor programs and a partnership with Iambic Therapeutics leveraging AI in drug discovery. Formed in 2014, Revolution Medicines, Inc. maintains its headquarters in Redwood City, California.

Company News

APIChatGPT

  • defenseworld.net

    Revolution Medicines, Inc. (NASDAQ:RVMDW) Sees Significant Increase in Short Interest

  • defenseworld.net

    Revolution Medicines, Inc. (NASDAQ:RVMDW) Short Interest Update